Prostate cancer

Prostate cancer is a common disease that affects men, usually in middle age or later. In this disorder, certain cells in the prostate become abnormal and multiply without control or order to form a tumor. The prostate is a gland that surrounds the male urethra and helps produce semen, the fluid that carries sperm.

Early prostate cancer usually does not cause pain, and most affected men exhibit no noticeable symptoms. Men are often diagnosed as the result of health screenings, such as a blood test for a substance called prostate specific antigen (PSA) or a medical procedure called a digital rectal exam. As the tumor grows larger, signs and symptoms can include difficulty starting or stopping the flow of urine, a feeling of not being able to empty the bladder completely, blood in the urine or semen, or pain with ejaculation. However, these changes can also occur with many other genitourinary conditions. Having one or more of these symptoms does not necessarily mean that a man has prostate cancer.

The severity and outcome of prostate cancer varies widely. Early-stage prostate cancer can usually be treated successfully, and some older men have prostate tumors that grow so slowly that they may never cause health problems during their lifetime, even without treatment. In other men, however, the cancer is much more aggressive; in these cases, prostate cancer can be life-threatening.

Some cancerous tumors can invade surrounding tissue and spread to other parts of the body. Tumors that begin at one site and then spread to other areas of the body are called metastatic cancers. The signs and symptoms of metastatic cancer depend on where the disease has spread. If prostate cancer spreads, cancerous cells most often appear in the lymph nodes, bones, lungs, liver, or brain. Bone metastases of prostate cancer most often cause pain in the lower back, pelvis, or hips.

A small percentage of all prostate cancers cluster in families. These hereditary cancers are associated with inherited gene mutations. Hereditary prostate cancers tend to develop earlier in life than non-inherited (sporadic) cases.

Frequency

About 1 in 7 men will be diagnosed with prostate cancer at some time during their life. In addition, studies indicate that many older men have undiagnosed prostate cancer that is non-aggressive and unlikely to cause symptoms or affect their lifespan. While most men who are diagnosed with prostate cancer do not die from it, this common cancer is still the second leading cause of cancer death among men in the United States.
More than 60 percent of prostate cancers are diagnosed after age 65, and the disorder is rare before age 40. In the United States, African Americans have a higher risk of developing prostate cancer than do men of other ethnic backgrounds, and they also have a higher risk of dying from the disease.

Causes

Cancers occur when genetic mutations build up in critical genes, specifically those that control cell growth and division or the repair of damaged DNA. These changes allow cells to grow and divide uncontrollably to form a tumor. In most cases of prostate cancer, these genetic changes are acquired during a man's lifetime and are present only in certain cells in the prostate. These changes, which are called somatic mutations, are not inherited. Somatic mutations in many different genes have been found in prostate cancer cells. Less commonly, genetic changes present in essentially all of the body's cells increase the risk of developing prostate cancer. These genetic changes, which are classified as germline mutations, are usually inherited from a parent. In people with germline mutations, changes in other genes, together with environmental and lifestyle factors, also influence whether a person will develop prostate cancer.

Inherited mutations in particular genes, such as \textit{BRCA1}, \textit{BRCA2}, and \textit{HOXB13}, account for some cases of hereditary prostate cancer. Men with mutations in these genes have a high risk of developing prostate cancer and, in some cases, other cancers during their lifetimes. In addition, men with \textit{BRCA2} or \textit{HOXB13} gene mutations may have a higher risk of developing life-threatening forms of prostate cancer.

The proteins produced from the \textit{BRCA1} and \textit{BRCA2} genes are involved in fixing damaged DNA, which helps to maintain the stability of a cell's genetic information. For this reason, the \textit{BRCA1} and \textit{BRCA2} proteins are considered to be tumor suppressors, which means that they help keep cells from growing and dividing too fast or in an uncontrolled way. Mutations in these genes impair the cell's ability to fix damaged DNA, allowing potentially damaging mutations to persist. As these defects accumulate, they can trigger cells to grow and divide uncontrollably and form a tumor.

The \textit{HOXB13} gene provides instructions for producing a protein that attaches (binds) to specific regions of DNA and regulates the activity of other genes. On the basis of this role, the protein produced from the \textit{HOXB13} gene is called a transcription factor. Like \textit{BRCA1} and \textit{BRCA2}, the \textit{HOXB13} protein is thought to act as a tumor suppressor. \textit{HOXB13} gene mutations may result in impairment of the protein's tumor suppressor function, resulting in the uncontrolled cell growth and division that can lead to prostate cancer.

Inherited variations in dozens of other genes have been studied as possible risk factors for prostate cancer. Some of these genes provide instructions for making proteins that interact with the proteins produced from the \textit{BRCA1}, \textit{BRCA2}, or \textit{HOXB13} genes. Others act as tumor suppressors through different pathways. Changes in these genes probably make only a small contribution to overall prostate cancer risk. However,
researchers suspect that the combined influence of variations in many of these genes may significantly impact a person’s risk of developing this form of cancer.

In many families, the genetic changes associated with hereditary prostate cancer are unknown. Identifying additional genetic risk factors for prostate cancer is an active area of medical research.

In addition to genetic changes, researchers have identified many personal and environmental factors that may contribute to a person’s risk of developing prostate cancer. These factors include a high-fat diet that includes an excess of meat and dairy and not enough vegetables, a largely inactive (sedentary) lifestyle, obesity, excessive alcohol use, or exposure to certain toxic chemicals. A history of prostate cancer in closely related family members is also an important risk factor, particularly if the cancer occurred at an early age.

**Inheritance Pattern**

Many cases of prostate cancer are not related to inherited gene changes. These cancers are associated with somatic mutations that occur only in certain cells in the prostate.

When prostate cancer is related to inherited gene changes, the way that cancer risk is inherited depends on the gene involved. For example, mutations in the \textit{BRCA1}, \textit{BRCA2}, and \textit{HOXB13} genes are inherited in an autosomal dominant pattern, which means one copy of the altered gene in each cell is sufficient to increase a person’s chance of developing cancer. In other cases, the inheritance of prostate cancer risk is unclear. It is important to note that people inherit an increased risk of cancer, not the disease itself. Not all people who inherit mutations in these genes will develop cancer.

**Other Names for This Condition**

- cancer of the prostate
- malignant neoplasm of the prostate
- prostate carcinoma
- prostate neoplasm
- prostatic cancer
- prostatic carcinoma
- prostatic neoplasm
Diagnosis & Management

Genetic Testing Information

• What is genetic testing?
  /primer/testing/genetictesting

• Genetic Testing Registry: Familial prostate cancer

• Genetic Testing Registry: Prostate cancer aggressiveness quantitative trait locus on chromosome 19

• Genetic Testing Registry: Prostate cancer, hereditary, 1

• Genetic Testing Registry: Prostate cancer, hereditary, 2

• Genetic Testing Registry: Prostate cancer, hereditary, 3

• Genetic Testing Registry: Prostate cancer, hereditary, 4

• Genetic Testing Registry: Prostate cancer, hereditary, 5

• Genetic Testing Registry: Prostate cancer, hereditary, 6

• Genetic Testing Registry: Prostate cancer, hereditary, 7

• Genetic Testing Registry: Prostate cancer, hereditary, 8

• Genetic Testing Registry: Prostate cancer, hereditary, 9

• Genetic Testing Registry: Prostate cancer, hereditary, 10

• Genetic Testing Registry: Prostate cancer, hereditary, 11

• Genetic Testing Registry: Prostate cancer, hereditary, 12

• Genetic Testing Registry: Prostate cancer, hereditary, 13

• Genetic Testing Registry: Prostate cancer, hereditary, 14
• Genetic Testing Registry: Prostate cancer, hereditary, 15

• Genetic Testing Registry: Prostate cancer, hereditary, X-linked 1

• Genetic Testing Registry: Prostate cancer, hereditary, X-linked 2

• Genetic Testing Registry: Prostate cancer/brain cancer susceptibility

• Giri VN, Knudsen KE, Kelly WK, Abida W, Andriole GL, Bangma CH, Bekelman
  JE, Benson MC, Blanco A, Burnett A, Catalona WJ, Cooney KA, Cooperberg M,
  Crawford DE, Den RB, Dicker AP, Eggener S, Fleschner N, Freedman ML, Hamdy
  FC, Hoffman-Censits J, Hurwitz MD, Hyatt C, Isaacs WB, Kane CJ, Kantoff P,
  Karnes RJ, Karsh LI, Klein EA, Lin DW, Loughlin KR, Lu-Yao G, Malkowicz SB,
  Mann MJ, Mark JR, McCue PA, Miner MM, Morgan T, Moul JW, Myers RE, Nielsen
  SM, Obeid E, Pavlovich CP, Peiper SC, Penson DF, Petrylak D, Pettaway CA,
  Pilarski R, Pinto PA, Poage W, Raj GV, Rebbeck TR, Robson ME, Rosenberg MT,
  Sandler H, Sartor O, Schaeffer E, Schwartz GF, Shahin MS, Shore ND, Shuch B,
  Soule HR, Tomlins SA, Trabulsi EJ, Uzzo R, Vander Griend DJ, Walsh PC, Weil
  CJ, Wender R, Gomella LG. Role of Genetic Testing for Inherited Prostate Cancer
  2017 Dec 13;JCO2017741173. doi: 10.1200/JCO.2017.74.1173. [Epub ahead of
  print]
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/29236593

Research Studies from ClinicalTrials.gov
• ClinicalTrials.gov
  https://clinicaltrials.gov/ct2/results?cond=%22prostate+cancer%22

Other Diagnosis and Management Resources
• Agency for Healthcare Research and Quality: Localized Prostate Cancer
  consumer/

• American College of Radiology: Prostate Cancer Radiation Treatment

• MedlinePlus Encyclopedia: Prostate Brachytherapy
  https://medlineplus.gov/ency/article/007385.htm

• MedlinePlus Encyclopedia: Prostate Cancer Staging
  https://medlineplus.gov/ency/patientinstructions/000397.htm

• MedlinePlus Encyclopedia: Prostate Cancer Treatment
  https://medlineplus.gov/ency/patientinstructions/000403.htm
• MedlinePlus Encyclopedia: Prostate-Specific Antigen (PSA) Blood Test
  https://medlineplus.gov/ency/article/003346.htm

• MedlinePlus Encyclopedia: Radical Prostatectomy
  https://medlineplus.gov/ency/article/007300.htm

• MedlinePlus Health Topic: Prostate Cancer Screening
  https://medlineplus.gov/prostatecancerscreening.html

• National Cancer Institute: Prostate-Specific Antigen (PSA) Test
  https://www.cancer.gov/types/prostate/psa-fact-sheet

• U.S. Preventive Services Task Force

Additional Information & Resources

Health Information from MedlinePlus
• Encyclopedia: Prostate Brachytherapy
  https://medlineplus.gov/ency/article/007385.htm

• Encyclopedia: Prostate Cancer
  https://medlineplus.gov/ency/article/000380.htm

• Encyclopedia: Prostate Cancer Staging
  https://medlineplus.gov/ency/patientinstructions/000397.htm

• Encyclopedia: Prostate Cancer Treatment
  https://medlineplus.gov/ency/patientinstructions/000403.htm

• Encyclopedia: Prostate-Specific Antigen (PSA) Blood Test
  https://medlineplus.gov/ency/article/003346.htm

• Encyclopedia: Radical Prostatectomy
  https://medlineplus.gov/ency/article/007300.htm

• Health Topic: Prostate Cancer
  https://medlineplus.gov/prostatecancer.html

• Health Topic: Prostate Cancer Screening
  https://medlineplus.gov/prostatecancerscreening.html

• Medical Tests: Prostate Specific Antigen (PSA) Test
  https://medlineplus.gov/lab-tests/prostate-specific-antigen-psa-test/

Genetic and Rare Diseases Information Center
• Familial prostate cancer

page 6
Additional NIH Resources

• National Cancer Institute: General Information About Prostate Cancer

• National Cancer Institute: Prostate-Specific Antigen (PSA) Test
  https://www.cancer.gov/types/prostate/psa-fact-sheet

• National Human Genome Research Institute: Learning About Prostate Cancer
  https://www.genome.gov/Genetic-Disorders/Prostate-Cancer

• National Institute on Aging: Prostate Problems
  https://www.nia.nih.gov/health/prostate-problems

Educational Resources

• Agency for Healthcare Research and Quality: Localized Prostate Cancer

• Centers for Disease Control and Prevention
  https://www.cdc.gov/cancer/prostate/

• MalaCards: prostate cancer
  https://www.malacards.org/card/prostate_cancer

• Orphanet: Familial prostate cancer
  https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=EN&Expert=1331

Patient Support and Advocacy Resources

• American Cancer Society

• CancerCare
  https://www.cancercare.org/diagnosis/prostate_cancer

• National Coalition for Cancer Survivorship
  https://www.canceradvocacy.org/

• Prostate Cancer Foundation
  https://www.pcf.org/

Scientific Articles on PubMed

• PubMed
  https://www.ncbi.nlm.nih.gov/pubmed?term=%28Prostatic+Neoplasms%5BMAJR%5D%29+AND+%28prostate+cancer%5BTI%5D%29+AND+genetics%5Bmh%5D+AND+review%5Bpt%5D+AND+english%5Bla%5D+AND+human%5Bmh%5D+AND+%22last+1800+days%22%5Bdp%5D
PROSTATE CANCER
http://omim.org/entry/176807

PROSTATE CANCER AGGRESSIVENESS QUANTITATIVE TRAIT LOCUS ON CHROMOSOME 19
http://omim.org/entry/607592

PROSTATE CANCER ANTIGEN 3
http://omim.org/entry/604845

PROSTATE CANCER-ASSOCIATED NONCODING RNA 1
http://omim.org/entry/615452

PROSTATE CANCER-ASSOCIATED TRANSCRIPT 4
http://omim.org/entry/609717

PROSTATE CANCER, HEREDITARY, 1
http://omim.org/entry/601518

PROSTATE CANCER, HEREDITARY, 2
http://omim.org/entry/614731

PROSTATE CANCER, HEREDITARY, 3
http://omim.org/entry/608656

PROSTATE CANCER, HEREDITARY, 4
http://omim.org/entry/608658

PROSTATE CANCER, HEREDITARY, 5
http://omim.org/entry/609299

PROSTATE CANCER, HEREDITARY, 6
http://omim.org/entry/609558

PROSTATE CANCER, HEREDITARY, 7
http://omim.org/entry/610321

PROSTATE CANCER, HEREDITARY, 8
http://omim.org/entry/602759

PROSTATE CANCER, HEREDITARY, 9
http://omim.org/entry/610997

PROSTATE CANCER, HEREDITARY, 10
http://omim.org/entry/611100

PROSTATE CANCER, HEREDITARY, 11
http://omim.org/entry/611955

PROSTATE CANCER, HEREDITARY, 12
http://omim.org/entry/611868
• PROSTATE CANCER, HEREDITARY, 13
  http://omim.org/entry/611928
• PROSTATE CANCER, HEREDITARY, 14
  http://omim.org/entry/611958
• PROSTATE CANCER, HEREDITARY, 15
  http://omim.org/entry/611959
• PROSTATE CANCER, HEREDITARY, X-LINKED 1
  http://omim.org/entry/300147
• PROSTATE CANCER, HEREDITARY, X-LINKED 2
  http://omim.org/entry/300704
• PROSTATE CANCER/BRAIN CANCER SUSCEPTIBILITY
  http://omim.org/entry/603688
• SOLUTE CARRIER FAMILY 45, MEMBER 3
  http://omim.org/entry/605097

Medical Genetics Database from MedGen

• Familial prostate cancer

Sources for This Summary

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/22974436

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/23759327
  Free article on PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4342117/

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/24239470

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/23248095
  Free article on PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4123124/

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/22522501
  Free article on PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3720154/
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/23589550
  Free article on PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3808235/

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/25199985
  Free article on PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4260983/

Reprinted from Genetics Home Reference:

Reviewed: April 2015
Published: March 31, 2020

Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
National Institutes of Health
Department of Health & Human Services